Preoperative ropivacaine injection is beneficial in pars plana vitrectomy

Article

Administering an injection of 5 mL of 0.75% ropivacaine before pars plana vitrectomy reduces postoperative discomfort in patients

Administering an injection of 5 mL of 0.75% ropivacaine before pars plana vitrectomy reduces postoperative discomfort in patients, reveals an investigation in the journal Retina.

The study, led by Dr Carl-Ludwig Schönfeld, Augenklinik Herzog Carl Theodor, Munich, Germany, included 60 patients each randomly assigned 0.75% ropivacaine with 75 IU of hyaluronidase as peribulbar injection of 1, 3, or 5 mL pre- or 5 mL postoperatively. There were also 30 control patients who didn’t receive any additional analgesic treatment, Both groups were compared 1, 3 and 24 hours postoperatively.

The control group experienced a higher rate of postoperative pain, compared to those in the ropivacine group. The 5 mL dosage of ropivacine was the most effective pain reliever, compared to the 1 mL or 3 mL injection. The injections provide a benefit in analgesic demand and postoperative discomfort.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.